A Dose Escalation Study of BIBF 1120 Together With Paclitaxel and Carboplatin in Patients With Advanced Stage Non-small-cell Lung Cancer

• Status: Completed
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

The primary objectives of this trial were to determine the MTD of BIBF 1120 in combination with carboplatin and paclitaxel, pharmacokinetics and objective response of treatment

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Boehringer Ingelheim
• Treatments: Albumin-Bound Paclitaxel; Carboplatin; Nintedanib; Paclitaxel

Criteria

Inclusion Criteria:

1. Male or female patients with histologically or cytologically confirmed Stage IIIB (including pleural effusion), IV or recurrent NSCLC

2. Bi-dimensionally measurable disease by one or more techniques (CT, MRI, X-ray)

3. Age 18 years or older

4. Life expectancy of at least three (3) months

5. Eastern Cooperative Oncology Group (ECOG) performance score 0 or 1

6. Written informed consent that is consistent with ICH-GCP guidelines

Exclusion Criteria:

1. Prior treatment for NSCLC including chemotherapy, biologic response modifier therapy, or any investigational drug

2. Participation in another clinical study within the past four weeks before start of therapy or concomitantly with this study

3. Active brain metastases (stable for <28 days, symptomatic, or requiring concurrent steroids or antiepileptic therapy)

4. Centrally located tumors with radiologic evidence (CT or MRI) of local invasion of major blood vessels

5. Cavitary or necrotic tumors

6. Sanguinous pleural effusion due to disease or pericardial effusion suspicious for disease

7. Radiotherapy to an area of measurable disease (unless disease progression had been documented following completion of therapy)

8. Radiotherapy within 4 weeks preceding Day 0

9. Other active malignancy diagnosed within the past 3 years (other than non-melanomatous skin cancer)

10. Gastrointestinal abnormalities that would interfere with intake or absorption of the study drug, such as a requirement for intravenous alimentation, prior surgical procedures affecting absorption, treatment for peptic ulcer disease within the last 6 months, active gastrointestinal bleeding unrelated to cancer (as evidenced by either hematemesis, hematochezia, or melena in the past 3 months and without endoscopic documented resolution), or malabsorption syndromes

11. Significant cardiovascular disease (i.e., uncontrolled hypertension, myocardial infarction within 6 months, unstable angina, serious cardiac arrhythmia, ≥NYHA Grade 2 congestive heart failure)

12. History of hemorrhagic or thrombotic event (including transient ischemic attacks) in the past 12 months

13. Clinically significant hemoptysis (1 teaspoon or more) in the past 3 months

14. Concurrent therapeutic anticoagulation (except heparin flush as needed for maintenance of an indwelling intravenous device) or antiplatelet therapy (except chronic low-dose daily aspirin <325 mg)

15. Known hypersensitivity to paclitaxel, carboplatin, or any of their excipients including Cremophor® (polyoxyethylated castor oil)

16. Absolute neutrophil count (ANC) ≤1,500/μl, platelet count ≤100,000/μl, or hemoglobin <9 gm/dL

17. Total bilirubin >1.5 mg/dL (26 μmol/L, SI Unit equivalent), alanine amino transferase (ALT) and/or aspartate amino transferase (AST) ≥1.5 X ULN,

18. Serum creatinine >1.5 mg/dL (>132 μmol/L, SI Unit equivalent)

19. Persistent hematuria or proteinuria (more than trace)

20. Women and men who are sexually active and unwilling to use a medically acceptable method of contraception

21. Pregnancy or breastfeeding

22. Known or suspected active alcohol or drug abuse

23. Patients unable to comply with the protocol